grant
BLOOD-BASED PROTEOMIC ASSAY FOR PANCREATIC CANCER DETECTION
Organization BAYLOR COLLEGE OF MEDICINELocation HOUSTON, UNITED STATESPosted 13 Sept 2024Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AntibodiesAssayBenchmarkingBenignBest Practice AnalysisBioassayBiologicalBiological AssayBiological MarkersBloodBlood PlasmaBlood Reticuloendothelial SystemBlood TestsCA-19-9CA-19-9 AntigenCA19-9Cancer Antigen 19-9Cancer DetectionCancersCarbohydrate Antigen 19-9CharacteristicsCholesterol HomeostasisClinicalClinical MarkersCohort StudiesCollaborationsConcurrent StudiesDetectionDevelopmentDiagnosisDiagnosticDisciplineDiseaseDisorderEDRNEarly Detection Research NetworkEarly DiagnosisGastrointestinal Cancer AntigenGuidelinesHealth SciencesHematologic TestsHematological TestsHematology TestingImmune responseInflammationLipidsLogistic RegressionsMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasuresMedical centerMedicineMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMethodsModelingNational Detection Research NetworkNeoplasm MetastasisPLCO studyPLCO trialPanINPancreas CancerPancreas Ductal AdenocarcinomaPancreatic CancerPancreatic Duct DysplasiaPancreatic Ductal AdenocarcinomaPancreatic Ductal DysplasiaPancreatic Intraepithelial NeoplasiaPancreatic cystic neoplasiaPatientsPerformancePhasePlasmaPlasma SerumProceduresProspective StudiesProstate, Lung, Colo-rectal and Ovarian (PLCO) Cancer Screening TrialProstate, Lung, Colo-rectal and Ovarian Cancer (PLCO) screening trialProstate, Lung, Colo-rectal, and Ovarian (PLCO)Prostate, Lung, Colo-rectal, and Ovarian Cancer Screening TrialProstate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening TrialProstate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trialProstate, Lung, Colorectal, and Ovarian (PLCO)Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialProstate, Lung, Ovarian (PLCO)Proteolytic RegulationProteomeProteomicsQuality ControlRegulation of ProteolysisReproducibilityResearch DesignReticuloendothelial System, Serum, PlasmaSample SizeSamplingScreening for cancerSecondary NeoplasmSecondary TumorSensitivity and SpecificitySialyl Lewis (A) AntigenSourceStatistical Data AnalysesStatistical Data AnalysisStatistical Data InterpretationStudy TypeSurvival RateTechniquesTechnologyTexasUniversitiesValidationVariantVariationbenchmarkbio-markersbiologicbiologic markerbiomarkerbiomarker arraybiomarker developmentbiomarker panelcancer biomarkerscancer markerscancer metastasiscandidate biomarkercandidate markercase controlcase-controlledcholesterol metabolismclinical biomarkersclinical diagnosisclinical validationclinically useful biomarkerscohortcollegecollegiatecomplement systemdetermine efficacydevelopmentaldisease controldisorder controlearly cancer detectionearly detectioneffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy testingevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentshigh risk grouphigh risk individualhigh risk peoplehigh risk populationhost responseimmune system responseimmunoresponseimprovedinstrumentinterestmachine learned algorithmmachine learning algorithmmachine learning based algorithmmalignancymarker panelneoplasm/cancerneovascularizationoperationoperationspancreas duct dysplasiapancreas ductal dysplasiapancreatic cystic lesionspancreatic cystic neoplasmspancreatic cystic tumorspancreatic malignancypre-clinicalpreclinicalprostate, lung, colorectal and ovarian cancer screening cohortprostate, lung, colorectal, and ovarian cancer screeningresponsescreening cancer patientsstatistical analysisstudy designtumor cell metastasisvalidations
Description preview
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is usually asymptomatic at an early stage.
In addition, metastases can be present even when the cancer size is relatively small. Most PDAC patients
succumb within 6 months of diagnosis with only 12% of patients surviving more than five years. Clinical assays
that can assist detection…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click